

DAFTAR PUSTAKA

Daftar Pustaka

- Andrews, L., Mutch, D.G., 2017. Hereditary Ovarian Cancer and Risk Reduction. *Best Practice & Research Clinical Obstetrics & Gynaecology* 41, 31–48. <https://doi.org/10.1016/j.bpobgyn.2016.10.017>
- Azimi, F., Scolyer, R.A., Rumcheva, P., Moncrieff, M., Murali, R., McCarthy, S.W., Saw, R.P., Thompson, J.F., 2012. Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. *JCO* 30, 2678–2683. <https://doi.org/10.1200/JCO.2011.37.8539>
- Baber, R., 2015. Menopausal hormone therapy and ovarian cancer. *J Mid-life Health* 6, 101. <https://doi.org/10.4103/0976-7800.165587>
- Brinton, L.A., Lamb, E.J., Moghissi, K.S., Scoccia, B., Althuis, M.D., Mabie, J.E., Westhoff, C.L., 2004. Ovarian Cancer Risk After the Use of Ovulation-Stimulating Drugs: *Obstetrics & Gynecology* 103, 1194–1203. <https://doi.org/10.1097/01.AOG.0000128139.92313.74>
- Calderon-Margalit, R., Friedlander, Y., Yanetz, R., Deutsch, L., Perrin, M.C., Kleinhaus, K., Tiram, E., Harlap, S., Paltiel, O., 2009. Preeclampsia and subsequent risk of cancer: update from the Jerusalem Perinatal Study. *American Journal of Obstetrics and Gynecology* 200, 63.e1-63.e5. <https://doi.org/10.1016/j.ajog.2008.06.057>
- Caziuc, A., Schlanger, D., Amarinei, G., Dindelegan, G.C., 2019. Can Tumor-Infiltrating Lymphocytes (TILs) Be a Predictive Factor for Lymph Nodes Status in Both Early Stage and Locally Advanced Breast Cancer? *JCM* 8, 545. <https://doi.org/10.3390/jcm8040545>
- Chan, J.K., Urban, R., Cheung, M.K., Osann, K., Husain, A., Teng, N.N., Kapp, D.S., Berek, J.S., Leiserowitz, G.S., 2006. Ovarian cancer in younger vs older women: a population-based analysis. *Br J Cancer* 95, 1314–1320. <https://doi.org/10.1038/sj.bjc.6603457>
- Chang, L.-C., Huang, C.-F., Lai, M.-S., Shen, L.-J., Wu, F.-L.L., Cheng, W.-F., 2018. Prognostic factors in epithelial ovarian cancer: A population-based study. *PLoS ONE* 13, e0194993. <https://doi.org/10.1371/journal.pone.0194993>

- Cibula, D., Widschwendter, M., Zikan, M., Dusek, L., 2011. Underlying mechanisms of ovarian cancer risk reduction after tubal ligation: Ovarian cancer risk after tubal ligation. *Acta Obstetrica et Gynecologica Scandinavica* 90, 559–563. <https://doi.org/10.1111/j.1600-0412.2011.01114.x>
- Coleman, R.L., Liu, J., Matsuo, K., Thaker, P.H., Westin, S.N., Sood, A.K., 2020. Carcinoma of the Ovaries and Fallopian Tubes, in: *Abeloff's Clinical Oncology*. Elsevier, pp. 1525-1543.e7. <https://doi.org/10.1016/B978-0-323-47674-4.00086-4>
- Cortez, A.J., Tudrej, P., Kujawa, K.A., Lisowska, K.M., 2018. Advances in ovarian cancer therapy. *Cancer Chemother Pharmacol* 81, 17–38. <https://doi.org/10.1007/s00280-017-3501-8>
- Desai, A., 2014. Epithelial ovarian cancer: An overview. *World Journal of Translational Medicine* 3, 1. <https://doi.org/10.5528/wjtm.v3.i1.1>
- Doubeni, C.A., Doubeni, A.R., Myers, A.E., 2016. Diagnosis and Management of Ovarian Cancer. *Am Fam Physician* 93, 937–944.
- Elmasry, K., Gayther, S.A., 2006. Ovarian cancer aetiology: facts and fiction. *J Fam Plann Reprod Health Care* 32, 82–86. <https://doi.org/10.1783/147118906776276297>
- Ferlay, J., Colombet, M., Soerjomataram, I., Mathers, C., Parkin, D.M., Piñeros, M., Znaor, A., Bray, F., 2019. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. *Int J Cancer* 144, 1941–1953. <https://doi.org/10.1002/ijc.31937>
- Foster, A.D., Sivarapatna, A., Gress, R.E., 2011. The aging immune system and its relationship with cancer. *Aging health* 7, 707–718. <https://doi.org/10.2217/ahe.11.56>
- Galon, J., Pagès, F., Marincola, F.M., Thurin, M., Trinchieri, G., Fox, B.A., Gajewski, T.F., Ascierto, P.A., 2012. The immune score as a new possible approach for the classification of cancer. *J Transl Med* 10, 1, 1479-5876-10–1. <https://doi.org/10.1186/1479-5876-10-1>
- Hilal, Z., Schultheis, B., Hartmann, F., Dogan, A., Cetin, C., Krentel, H., Schiermeier, S., Tempfer, C.B., 2016. What Characterizes Long-term Survivors of Recurrent Ovarian Cancer? Case Report and Review of the Literature. *AR* 36, 5365–5372. <https://doi.org/10.21873/anticancer.11110>

- Hsieh, S.-F., Lau, H.-Y., Wu, H.-H., Hsu, H.-C., Twu, N.-F., Cheng, W.-F., 2019. Prognostic Factors of Early Stage Epithelial Ovarian Carcinoma. *IJERPH* 16, 637. <https://doi.org/10.3390/ijerph16040637>
- Hwang, C., Lee, S., Lee, J., Kim, K., Suh, D., Kwon, B., Choi, K., 2019. Stromal tumor-infiltrating lymphocytes evaluated on H&E-stained slides are an independent prognostic factor in epithelial ovarian cancer and ovarian serous carcinoma. *Oncol Lett.* <https://doi.org/10.3892/ol.2019.10095>
- Indiralia, A., Rahniayu, A., Mustokoweni, S., 2018. Perbedaan Ekspresi FOXP3+ dan CD8+ Tumor Infiltrating Lymphocytes Karsinoma Payudara pada Berbagai Stadium T. *Indonesia Journal of Cancer* 12, 07–13.
- Ingold Heppner, B., Loibl, S., Denkert, C., 2016. Tumor-Infiltrating Lymphocytes: A Promising Biomarker in Breast Cancer. *Breast Care* 11, 96–100. <https://doi.org/10.1159/000444357>
- James, F.R., Jiminez-Linan, M., Alsop, J., Mack, M., Song, H., Brenton, J.D., Pharoah, P.D.P., Ali, H.R., 2017. Association between tumour infiltrating lymphocytes, histotype and clinical outcome in epithelial ovarian cancer. *BMC Cancer* 17, 657. <https://doi.org/10.1186/s12885-017-3585-x>
- Jeske, S.S., Schuler, P.J., Doescher, J., Theodoraki, M.N., Laban, S., Brunner, C., Hoffmann, T.K., Wigand, M.C., 2020. Age-related changes in T lymphocytes of patients with head and neck squamous cell carcinoma. *Immun Ageing* 17, 3. <https://doi.org/10.1186/s12979-020-0174-7>
- Kim, A., Ueda, Y., Naka, T., Enomoto, T., 2012. Therapeutic strategies in epithelial ovarian cancer. *J Exp Clin Cancer Res* 31, 14. <https://doi.org/10.1186/1756-9966-31-14>
- Kim, J.Y., Kim, C.H., Lee, Y., Lee, J.H., Chae, Y.-S., 2017. Tumour infiltrating lymphocytes are predictors of lymph node metastasis in early gastric cancers. *Pathology* 49, 589–595. <https://doi.org/10.1016/j.pathol.2017.06.003>
- Kumar, V., Abbas, A.K., Aster, J.C., Robbins, S.L., 2013. Robbins basic pathology, 9th ed. ed. Elsevier/Saunders, Philadelphia, PA.
- Li, J., Wang, J., Chen, R., Bai, Y., Lu, X., 2017. The prognostic value of tumor-infiltrating T lymphocytes in ovarian cancer. *Oncotarget* 8, 15621–15631. <https://doi.org/10.18632/oncotarget.14919>
- Massi, D., Susini, T., Savino, L., Boddi, V., Amunni, G., Colafranceschi, M., 1996. Epithelial ovarian tumors in the reproductive age group: age is not an independent prognostic factor. *Cancer* 77, 1131–1136.

- Matz, M., Coleman, M., Allemani, C., 2019. 60 Histological subtypes of ovarian cancer: worldwide distribution and comparison of survival (CONCORD-3), in: Regional Plenary. Presented at the IGCS Annual 2019 Meeting Abstracts, BMJ Publishing Group Ltd, p. A33.2-A33. <https://doi.org/10.1136/ijgc-2019-IGCS.60>
- Mok, S.C., Kwong, J., Welch, W.R., Samimi, G., Ozbun, L., Bonome, T., Birrer, M.J., Berkowitz, R.S., Wong, K.-K., 2007. Etiology and Pathogenesis of Epithelial Ovarian Cancer. *Disease Markers* 23, 367–376. <https://doi.org/10.1155/2007/474320>
- Momenimovahed, Z., Tiznobaik, A., Taheri, S., Salehiniya, H., 2019. Ovarian cancer in the world: epidemiology and risk factors. *International Journal of Women's Health* 11, 287–299. <https://doi.org/10.2147/IJWH.S197604>
- Noela, F., Nuryanto, K.H., 2016. Epidemiology Data of Ovarian Cancer in Dr. Cipto Mangunkusumo Hospital, Jakarta. *Indones J Obstet Gynecol* 101. <https://doi.org/10.32771/inajog.v4i2.84>
- Novoa Vargas, A., 2014. Natural History of Ovarian Cancer. *J Cancer Sci Ther* 06. <https://doi.org/10.4172/1948-5956.1000278>
- Ostroumov, D., Fekete-Drimusz, N., Saborowski, M., Kühnel, F., Woller, N., 2018. CD4 and CD8 T lymphocyte interplay in controlling tumor growth. *Cell. Mol. Life Sci.* 75, 689–713. <https://doi.org/10.1007/s00018-017-2686-7>
- Paul, S., Lal, G., 2017. The Molecular Mechanism of Natural Killer Cells Function and Its Importance in Cancer Immunotherapy. *Front. Immunol.* 8, 1124. <https://doi.org/10.3389/fimmu.2017.01124>
- Pavone, M.E., Lyttle, B., 2015. Endometriosis and ovarian cancer: links, risks, and challenges faced. *IJWH* 663. <https://doi.org/10.2147/IJWH.S66824>
- Pujani, M., Jain, H., Chauhan, V., Agarwal, C., Singh, K., Singh, M., 2020. Evaluation of Tumor infiltrating lymphocytes in breast carcinoma and their correlation with molecular subtypes, tumor grade and stage. *Breast Dis* 39, 61–69. <https://doi.org/10.3233/BD-200442>
- Ravelli, A., Roviello, G., Cretella, D., Cavazzoni, A., Biondi, A., Cappelletti, M.R., Zanotti, L., Ferrero, G., Ungari, M., Zanconati, F., Bottini, A., Alfieri, R., Petronini, P.G., Generali, D., 2017. Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility. *Tumour Biol.* 39, 101042831769502. <https://doi.org/10.1177/1010428317695023>

- Salgado, R., Denkert, C., Demaria, S., Sirtaine, N., Klauschen, F., Pruner, G., Wienert, S., Van den Eynden, G., Baehner, F.L., Penault-Llorca, F., Perez, E.A., Thompson, E.A., Symmans, W.F., Richardson, A.L., Brock, J., Criscitiello, C., Bailey, H., Ignatiadis, M., Floris, G., Sparano, J., Kos, Z., Nielsen, T., Rimm, D.L., Allison, K.H., Reis-Filho, J.S., Loibl, S., Sotiriou, C., Viale, G., Badve, S., Adams, S., Willard-Gallo, K., Loi, S., 2015. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. *Annals of Oncology* 26, 259–271. <https://doi.org/10.1093/annonc/mdl450>
- Santoiemma, P.P., Powell, D.J., 2015. Tumor infiltrating lymphocytes in ovarian cancer. *Cancer Biology & Therapy* 16, 807–820. <https://doi.org/10.1080/15384047.2015.1040960>
- Sato, E., Olson, S.H., Ahn, J., Bundy, B., Nishikawa, H., Qian, F., Jungbluth, A.A., Frosina, D., Gnjjatic, S., Ambrosone, C., Kepner, J., Odunsi, T., Ritter, G., Lele, S., Chen, Y.-T., Ohtani, H., Old, L.J., Odunsi, K., 2005. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. *Proceedings of the National Academy of Sciences* 102, 18538–18543. <https://doi.org/10.1073/pnas.0509182102>
- Schietinger, A., Arina, A., Liu, R.B., Wells, S., Huang, J., Engels, B., Bindokas, V., Bartkowiak, T., Lee, D., Herrmann, A., Piston, D.W., Pittet, M.J., Lin, P.C., Zal, T., Schreiber, H., 2013. Longitudinal confocal microscopy imaging of solid tumor destruction following adoptive T cell transfer. *OncoImmunology* 2, e26677. <https://doi.org/10.4161/onci.26677>
- Subhash, V.V., Yeo, M.S., Tan, W.L., Yong, W.P., 2015. Strategies and Advancements in Harnessing the Immune System for Gastric Cancer Immunotherapy. *Journal of Immunology Research* 2015, 1–14. <https://doi.org/10.1155/2015/308574>
- Vargas, A., 2014. Natural history of ovarian cancer. *ecancer*. <https://doi.org/https://doi.org/10.3332/ecancer.2014.465>
- Webb, P.M., Jordan, S.J., 2017. Epidemiology of epithelial ovarian cancer. *Best Practice & Research Clinical Obstetrics & Gynaecology* 41, 3–14. <https://doi.org/10.1016/j.bpobgyn.2016.08.006>
- Winter, W.E., Maxwell, G.L., Tian, C., Carlson, J.W., Ozols, R.F., Rose, P.G., Markman, M., Armstrong, D.K., Muggia, F., McGuire, W.P., 2007. Prognostic Factors for Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study. *JCO* 25, 3621–3627. <https://doi.org/10.1200/JCO.2006.10.2517>

- Wu, A.H., Pearce, C.L., Lee, A.W., Tseng, C., Jotwani, A., Patel, P., Pike, M.C., 2017. Timing of births and oral contraceptive use influences ovarian cancer risk: Timing of births influences ovarian cancer risk. *Int. J. Cancer* 141, 2392–2399. <https://doi.org/10.1002/ijc.30910>
- Yang, Yanfei, Yang, Yang, Yang, J., Zhao, X., Wei, X., 2020. Tumor Microenvironment in Ovarian Cancer: Function and Therapeutic Strategy. *Front Cell Dev Biol* 8, 758. <https://doi.org/10.3389/fcell.2020.00758>
- Zgura, A., Galesa, L., Bratila, E., Anghel, R., 2018. Relationship between Tumor Infiltrating Lymphocytes and Progression in Breast Cancer. *Maedica (Bucur)* 13, 317–320. <https://doi.org/10.26574/maedica.2018.13.4.317>
- Zhang, L., Conejo-Garcia, J.R., Katsaros, D., Gimotty, P.A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M.N., Rubin, S.C., Coukos, G., 2003. Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer. *N Engl J Med* 348, 203–213. <https://doi.org/10.1056/NEJMoa020177>
- Zhang, Y., Luo, G., Li, M., Guo, P., Xiao, Y., Ji, H., Hao, Y., 2019. Global patterns and trends in ovarian cancer incidence: age, period and birth cohort analysis. *BMC Cancer* 19, 984. <https://doi.org/10.1186/s12885-019-6139-6>